Dr. Okorie is board certified in pediatric pulmonology, sleep medicine and general pediatrics and joined the Division of Pediatric Pulmonary, Asthma and Sleep Medicine in 2018. She obtained her medical degree and Master’s in Public Health at the University of Arizona before going on to a residency and chief residency in pediatrics at Oregon Health & Science University. She completed her fellowship training in both pediatric pulmonary medicine and sleep medicine at Stanford University. She has a passion for medical education and serves as an Associate Program Director for the Pediatric Residency Program at Stanford.
She treats children with a variety of lung diseases, including: asthma, chronic cough, cystic fibrosis, chronic respiratory failure, and chronic lung disease of prematurity. Her additional training in sleep medicine allows her expertise to treat sleep disorders, including: sleep disordered breathing, parasomnias, narcolepsy, restless legs syndrome, and insomnia.
- Pediatric Pulmonary
- Sleep Medicine
- Insomnia Disorders
- Sleep Related Movement Disorders
- Sleep Disordered Breathing
Clinical Assistant Professor, Pediatrics - Pulmonary Medicine
Associate Program Director, Stanford Pediatrics Residency Program, Stanford School of Medicine, Department of Pediatrics (2019 - Present)
Faculty Coach, Stanford Pediatrics Residency Program, Stanford School of Medicine, Department of Pediatrics (2018 - 2020)
Boards, Advisory Committees, Professional Organizations
Member, American College of Chest Physicians, Sleep Networks Committee (2019 - Present)
Member, American Thoracic Society Education Committee (2019 - Present)
Board Certification: American Board of Pediatrics, Sleep Medicine (2019)
Board Certification, American Board of Pediatrics, Pediatric Pulmonary Medicine (2018)
Board Certification, American Board of Pediatrics, Pediatrics (2013)
Fellowship, Stanford University, Department of Psychiatry, Sleep Medicine (2018)
Fellowship, Stanford University, Department of Pediatrics, Pediatric Pulmonary Medicine (2017)
Chief Residency, Oregon Health & Science University, Pediatrics (2014)
Residency, Oregon Health & Science University, Pediatrics (2013)
MD, University of Arizona College of Medicine, Medicine (2010)
MPH, Mel and Enid Zuckerman College of Public Health, Public Health (2010)
BA, Stanford University, English Literature (2003)
- The Use of Auto-Titrating Continuous Positive Airway Pressure (AutoCPAP) for Obstructive Sleep Apnea Syndrome in Children with Obesity CHILDREN-BASEL 2021; 8 (12)
Positive Airway Pressure Therapy for Pediatric Obstructive Sleep Apnea.
Children (Basel, Switzerland)
2021; 8 (11)
Pediatric obstructive sleep apnea syndrome (OSAS) is a disorder of breathing during sleep, characterized by intermittent or prolonged upper airway obstruction that can disrupt normal ventilation and/or sleep patterns. It can affect an estimated 2-4% of children worldwide. Untreated OSAS can have far reaching consequences on a child's health, including low mood and concentration as well as metabolic derangements and pulmonary vascular disease. Most children are treated with surgical intervention (e.g., first-line therapy, adenotonsillectomy); however, for those for whom surgery is not indicated or desired, or for those with postoperative residual OSAS, positive airway pressure (PAP) therapy is often employed. PAP therapy can be used to relieve upper airway obstruction as well as aid in ventilation. PAP therapy is effective in treatment of OSAS in children and adults, although with pediatric patients, additional considerations and limitations exist. Active management and care for various considerations important to pediatric patients with OSAS can allow PAP to be an effective and safe therapy in this population.
View details for DOI 10.3390/children8110979
View details for PubMedID 34828692
ATS Core Curriculum 2021. Pediatric Pulmonary Medicine: Pulmonary Infections.
2021; 2 (3): 452-467
The following is a concise review of the Pediatric Pulmonary Medicine Core reviewing pediatric pulmonary infections, diagnostic assays, and imaging techniques presented at the 2021 American Thoracic Society Core Curriculum. Molecular methods have revolutionized microbiology. We highlight the need to collect appropriate samples for detection of specific pathogens or for panels and understand the limitations of the assays. Considerable progress has been made in imaging modalities for detecting pediatric pulmonary infections. Specifically, lung ultrasound and lung magnetic resonance imaging are promising radiation-free diagnostic tools, with results comparable with their radiation-exposing counterparts, for the evaluation and management of pulmonary infections. Clinicians caring for children with pulmonary disease should ensure that patients at risk for nontuberculous mycobacteria disease are identified and receive appropriate nontuberculous mycobacteria screening, monitoring, and treatment. Children with coronavirus disease (COVID-19) typically present with mild symptoms, but some may develop severe disease. Treatment is mainly supportive care, and most patients make a full recovery. Anticipatory guidance and appropriate counseling from pediatricians on social distancing and diagnostic testing remain vital to curbing the pandemic. The pediatric immunocompromised patient is at risk for invasive and opportunistic pulmonary infections. Prompt recognition of predisposing risk factors, combined with knowledge of clinical characteristics of microbial pathogens, can assist in the diagnosis and treatment of specific bacterial, viral, or fungal diseases.
View details for DOI 10.34197/ats-scholar.2021-0034RE
View details for PubMedID 34667993
The Use of Auto-titrating Continuous Positive Airway Pressure (autoCPAP) for Obstructive Sleep Apnea Syndrome in Children with Obesity
AMER THORACIC SOC. 2021
Positive airway pressure can be an effective and safe therapy for children with obstructive sleep apnea syndrome (OSAS). Few studies have assessed the safety and efficacy of autoCPAP in pediatric patients with obesity.This was a retrospective chart review of children with obesity (Body Mass Index (BMI) > 99th percentile), ages 2-18, diagnosed with OSAS (Obstructive Apnea-Hypopnea Index (OAHI) > 1/h) and used autoCPAP with 30-day adherence. Exclusion criteria included patients with complex comorbidities. Adherence was defined as autoCPAP use ≥4 h/night for at least 21/30 days. Baseline PSG OAHI was compared to the AHI from the 30-day autoCPAP compliance report. We also compared autoCPAP 30-day 95th percentile pressures with the pressures from PAP titration.The study included 19 children, ranging 5-15 years old. The median BMI was 99.6th percentile and average adherence was 25/30 nights with mean of 7.3 h/night. The median OAHI was 12.3/h on baseline PSG and the 30-day autoCPAP download AHI decreased to 1.7/h. No adverse outcomes were identified. The average difference between 95th percentile autoCPAP pressure and PAP titration pressure was 0.89 cmH20.Our study suggests autoCPAP is effective and safe for the treatment of OSAS in pediatric patients with obesity. Using autoCPAP may reduce delays in treatment. Additional research is needed to verify the long-term effectiveness of autoCPAP in this population.
View details for Web of Science ID 000685468903106
View details for PubMedID 34943400
ATS Core Curriculum 2020. Pediatric Pulmonary Medicine.
2020; 1 (4): 456–75
The American Thoracic Society Core Curriculum updates clinicians annually in adult and pediatric pulmonary disease, medical critical care, and sleep medicine, in a 3- to 4-year recurring cycle of topics. These topics will be presented at the 2020 International Conference. Below is the pediatric pulmonary medicine core, including pediatric hypoxemic respiratory failure; modalities in noninvasive management of chronic respiratory failure in childhood; surgical and nonsurgical management of congenital lung malformations; an update on smoke inhalation lung injury; an update on vaporizers, e-cigarettes, and other electronic delivery systems; pulmonary complications of sarcoidosis; pulmonary complications of congenital heart disease; and updates on the management of congenital diaphragmatic hernia.
View details for DOI 10.34197/ats-scholar.2020-0022RE
View details for PubMedID 33870313
- The nocturnal-polysomnogram and "non-hypoxic sleep-disordered-breathing" in children SLEEP MEDICINE 2019; 60: 31–44
- Sleep The Handbook of Personal Health and Wellbeing for Physicians and Trainees edited by Weiss Roberts, L., Trockel, M. Springer International Publishing. 2019
The nocturnal-polysomnogram and "non-hypoxic sleep-disordered-breathing" in children.
OBJECTIVE: To characterize sleep-disordered breathing patterns not related to hypoxia resulting in fragmented sleep in children.METHODS: We reviewed the polysomnogram (PSG) data of children with sleep complaints who were being evaluated for sleep-disordered breathing and had an apnea-hypopnea-index≤3. These data were compared to the recordings of the same children with nasal CPAP administered for one night and to 60 control subjects (children without any sleep complaints). A subgroup of children was monitored with esophageal manometry, but nasal cannula flow data was recorded in all cases.RESULTS: Abnormal breathing patterns, particularly flow limitation, could be seen with more severity and frequency compared to apnea or hypopnea. The observed abnormal breathing patterns were associated with EEG disturbances.CONCLUSIONS: Patterns such as flow-limitation, mouth-breathing, changes in inspiratory and expiratory time, rib-cage and expiratory muscle activity, transcutaneous CO2 electrode changes and snoring noises are all variables that should be systematically reviewed when analyzing nocturnal PSG. Current scoring guidelines emphasizes apnea-hypopnea and hypoxic-sleep disordered breathing and therefore treatment is often much delayed in this population of children with evidence of abnormal breathing patterns. Analysis of the various patterns of abnormal breathing noted above allows recognition of "non-hypoxic" sleep-disordered-breathing (SDB).
View details for PubMedID 30578113
Allergic Bronchopulmonary Aspergillosis.
Journal of fungi (Basel, Switzerland)
2016; 2 (2)
Allergic bronchopulmonary aspergillosis (ABPA), a progressive fungal allergic lung disease, is a common complication of asthma or cystic fibrosis. Although ABPA has been recognized since the 1950s, recent research has underscored the importance of Th2 immune deviation and granulocyte activation in its pathogenesis. There is also strong evidence of widespread under-diagnosis due to the complexity and lack of standardization of diagnostic criteria. Treatment has long focused on downregulation of the inflammatory response with prolonged courses of oral glucocorticosteroids, but more recently concerns with steroid toxicity and availability of new treatment modalities has led to trials of oral azoles, inhaled amphotericin, pulse intravenous steroids, and subcutaneously-injected anti-IgE monoclonal antibody omalizumab, all of which show evidence of efficacy and reduced toxicity.
View details for DOI 10.3390/jof2020017
View details for PubMedID 29376934
View details for PubMedCentralID PMC5753079
Diagnosis And Management Of Sporadic Pulmonary Arteriovenous Malformation Not Associated With Hereditary Hemorrhagic Telangiectasia
AMER THORACIC SOC. 2016
View details for Web of Science ID 000390749605287
A Presentation Of Hepatopulmonary Syndrome In A Five Year Old During Evaluation For Miliary Tuberculosis
AMER THORACIC SOC. 2015
View details for Web of Science ID 000377582808172
Successful Treatment Of Mineral Oil Associated Lipoid Pneumonia In An Infant
AMER THORACIC SOC. 2013
View details for Web of Science ID 000209839101412